NCT01498484: Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies |
|
|
| Completed | 2 | 87 | US | EBV-specific T cells (EBV-CTLs), tabelecleucel, tab-celĀ®, ATA129 | Atara Biotherapeutics, Memorial Sloan Kettering Cancer Center | EBV-induced Lymphomas, EBV-associated Malignancies, Transplant Patients With EBV Viremia at High Risk for Developing a Recurrent EBV Lymphoma | 07/19 | 07/19 | | |
| Recruiting | 2 | 190 | Europe, US | Tabelecleucel, tab-celĀ®, ATA129, EBV-CTLs | Atara Biotherapeutics | Epstein-Barr Virus (EBV)-Associated Diseases, EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD), EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (EBV+ AID LPD), EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (EBV+ CNS PTLD), EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications, EBV+ Sarcomas, Leiomyosarcoma | 06/27 | 05/29 | | |